RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
A large proportion of women with menstruating potential with newly diagnosed VTE or atrial
fibrillation, treated with apixaban will have less menstrual blood loss than patients
randomized to rivaroxaban.